Facilitating Applications for Paediatric Investigation Plans
![](/46/pdcnewsitem/03/37/17/fZgrPh89WLCM4Re.png)
The European Commission has published a revised guideline on applications for paediatric investigation plans, or PIPs, in the Official Journal of the European Union. The new guideline is expected to facilitate the application process. It is intended for all medicines developers.
Since the European Paediatric Regulation came into force in 2007, pharmaceutical companies have had a legal obligation to develop plans to evaluate medicines in children (known as paediatric investigation plans) as part of the development of all new medicines, unless they obtain an exemption (known as a waiver). In some cases, a similar obligation also applies to medicines that are already authorised in the European Union (EU).
The first guideline describing the format and content of applications for paediatric investigation plans was released in September 2008.The Commission has conducted a review of this guideline to take into account experience gained as well as feedback received from medicines developers.
Amongst other elements, the new guideline:
establishes key elements that should be included in paediatric investigation plans,
introduces increased flexibility into the application process,
incorporates new study concepts, such as extrapolation of results and modelling,
clarifies requirements for the compliance check.
The text of the guideline is available in all EU languages.
The new guideline is applicable as of 30 Spetember 2014. However, the European Medicines Agency (EMA) will continue to accept paediatric investigation plans that have been prepared in accordance with the previous guideline until the end of 2014. The EMA will update its set of documentations related to PIPs, including templates, application forms and questions and answers, to reflect these changes by the end of October 2014.
The EMA’s Paediatric Committee (PDCO) reviews all applications for PIPs and waivers and issues an opinion on the clinical studies, pharmaceutical forms and tests that must be performed in children.
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance